The $137M Bet on Cancer's Smart Bombs
Sidewinder Therapeutics just raised $137 million without a single drug in human testing. Its secret weapon: bispecific ADCs that target cancer cells with two signals instead of one, like a bouncer checking two forms of ID. The investor list is stacked, but the real test is still years away.
A Startup Nobody's Heard of Just Raised More Than Most Biotechs Dream Of
Sidewinder Therapeutics has been around for barely three years. It has zero drugs in human trials. It hasn't filed a single application with the FDA. And yet, investors just handed it $137 million in a funding round that was oversubscribed.
That's not a typo. A pre-clinical biotech company in San Diego pulled in nine figures from some of the biggest names in healthcare investing. The round brings Sidewinder's total haul to $162 million since its founding in 2023. For a company most people have never heard of, that's a staggering amount of confidence.
So what does Sidewinder have that's worth all that money? The answer involves a clever twist on one of oncology's hottest drug types.
ADCs: Cancer Treatment's Guided Missiles
To understand Sidewinder, you need to understand antibody-drug conjugates, or ADCs. Think of them as guided missiles for cancer. A traditional chemotherapy drug is like carpet-bombing a city to hit one building: it kills cancer cells, sure, but it also destroys a lot of healthy tissue along the way. An ADC, by contrast, attaches a toxic payload to an antibody that's designed to seek out a specific marker on tumor cells. The antibody finds the target, locks on, gets pulled inside the cancer cell, and releases its poison.
It's an elegant concept. The problem? Most ADCs are guided by a single marker. And that marker often shows up on healthy cells too, which means the guided missile sometimes hits the wrong building. This leads to side effects that limit how much drug you can give, which limits how well it works.
Sidewinder thinks it has a better approach.
The Bispecific Twist
Instead of homing in on one target, Sidewinder's ADCs are bispecific, meaning they recognize two markers at the same time. Specifically, they look for pairs of receptors that appear together on tumor cells but rarely show up as a duo on healthy tissue.
Imagine you're looking for someone in a crowd. Searching for "person wearing a red hat" might match dozens of people. But "person wearing a red hat a green scarf" narrows it down dramatically. That's the logic behind Sidewinder's platform: by requiring two signals instead of one, the drug becomes far more selective about which cells it attacks.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
